Eureka tackles major challenges for T cells in solid tumors with $45M E round, Lyell deal

Eureka is moving its TCR-mimicking antibodies forward with a new partner and new funding

Eureka is taking the next steps to bring cell therapies into solid tumors with a $45 million series E round and a new partnership with solid tumor cell therapy company Lyell.

Eureka Therapeutics Inc. and Lyell Immunopharma Inc., which led the venture round, are teaming up to develop T cell therapies against several solid tumor targets; details are undisclosed.

There are three main challenges to bringing T cell

Read the full 682 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE